The present invention relates to the use of novel macrocyclic compounds of Formula I,
wherein the variables Q, Q
1
, Q
2
, Q
3
, and Q
4
are defined as described herein, which inhibit JAK and are useful for the treatment of auto-immune and inflammatory diseases.